Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX ...

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at manilatimes.net →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Tenax Therapeutics reported Phase 3 LEVEL trial results of TNX-103 in PH-HFpEF patients, missing the primary endpoint of 6-minute walk distance improvement but showing significant biomarker improvements and benefits in sicker subgroups. The company plans to engage the FDA for revised registrational strategy based on these data.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clear path to engage the FDA on a tailored development plan after these Phase 3 results narrow the target patient group. Your immediate task is to prepare for the Type C meeting focusing on patients with greater disease burden showing positive response.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialph-hfpefbiomarkersregulatory-pathcardiologytnx-103